Search Results - "Thomes Pepin, J."
-
1
LBA41 Durvalumab (durva) plus carboplatin/paclitaxel (CP) followed by maintenance (mtx) durva ± olaparib (ola) as a first-line (1L) treatment for newly diagnosed advanced or recurrent endometrial cancer (EC): Results from the phase III DUO-E/GOG-3041/ENGOT-EN10 trial
Published in Annals of oncology (01-10-2023)Get full text
Journal Article -
2
LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)
Published in Annals of oncology (01-09-2020)Get full text
Journal Article -
3
40MO First-line (1L) durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib for endometrial cancer (EC) (DUO-E): Objective response rate (ORR), duration of response (DoR) and time to treatment discontinuation or death (TDT) by mismatch repair (MMR) status
Published in ESMO open (01-06-2024)Get full text
Journal Article -
4
44O Safety and efficacy results in patients who received dose modifications in the phase III MIRASOL (GOG 3045/ENGOT-ov55) trial of mirvetuximab soravtansine vs investigator’s choice chemotherapy (ICC) in platinum-resistant ovarian cancer (PROC) with high folate receptor-alpha expression
Published in ESMO open (01-06-2024)Get full text
Journal Article -
5
Wound morbidity of groin node dissection performed after radiation for vulvar cancer
Published in Gynecologic oncology (01-10-2013)Get full text
Journal Article